FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1104-1110 March 11, 2004 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Durham, P. L. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Calcitonin gene–related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks.

Methods In an international, multicenter, double-blind, randomized clinical trial of BIBN 4096 BS, a highly specific and potent nonpeptide CGRP-receptor antagonist, 126 patients with migraine received one of the following: placebo or 0.25, 0.5, 1, 2.5, 5, or 10 mg of BIBN 4096 BS intravenously over a period of 10 minutes. A group-sequential adaptive treatment-assignment design was used to minimize the number of patients exposed.

Results The 2.5-mg dose was selected, with a response rate of 66 percent, as compared with 27 percent for placebo (P=0.001). The BIBN 4096 BS group as a whole had a response rate of 60 percent. Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief. An effect was apparent after 30 minutes and increased over the next few hours. The overall rate of adverse events was 25 percent after the 2.5-mg dose of the drug and 20 percent for the BIBN 4096 BS group as a whole, as compared with 12 percent for placebo. The most frequent side effect was paresthesia. There were no serious adverse events.

Conclusions The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.

Source Information

From the Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark (J.O.); the Department of Neurology, University of Essen, Essen, Germany (H.-C.D.); the Department of Neurology, University Hospital, Münster, Germany (I.W.H.); the Institute of Neurology, London (P.J.G.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn. (D.H., L.M.L.); and Boehringer Ingelheim Pharma, Ingelheim, Germany (U.M., S.P.).

Address reprint requests to Dr. Olsen at the University of Copenhagen, Department of Neurology, Glostrup Hospital, 2600 Glostrup, Copenhagen, Denmark, or at jeol{at}glostruphosp.kbhamt.dk.

Full Text of this Article

This article has been cited by other articles:

• Recober, A., Kuburas, A., Zhang, Z., Wemmie, J. A., Anderson, M. G., Russo, A. F. (2009). Role of Calcitonin Gene-Related Peptide in Light-Aversive Behavior: Implications for Migraine. J. Neurosci. 29: 8798-8804 [Abstract] [Full Text]  
• Bailey, D. M., Taudorf, S., Berg, R. M.G., Jensen, L. T., Lundby, C., Evans, K. A., James, P. E., Pedersen, B. K., Moller, K. (2009). Transcerebral Exchange Kinetics of Nitrite and Calcitonin Gene-Related Peptide in Acute Mountain Sickness: Evidence Against Trigeminovascular Activation?. Stroke 40: 2205-2208 [Abstract] [Full Text]  
• Cady, R. K. (2009). The Future of Migraine: Beyond Just Another Pill. Mayo Clin Proc. 84: 397-399 [Full Text]  
• Meng, J., Ovsepian, S. V., Wang, J., Pickering, M., Sasse, A., Aoki, K. R., Lawrence, G. W., Dolly, J. O. (2009). Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential. J. Neurosci. 29: 4981-4992 [Abstract] [Full Text]  
• Ambalavanar, R., Dessem, D. (2009). Emerging Peripheral Receptor Targets for Deep-tissue Craniofacial Pain Therapies. JDR 88: 201-211 [Abstract] [Full Text]  
• Regan, C. P., Stump, G. L., Kane, S. A., Lynch, J. J. Jr. (2009). Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis. J. Pharmacol. Exp. Ther. 328: 571-578 [Abstract] [Full Text]  
• Goadsby, P. J. (2009). The vascular theory of migraine--a great story wrecked by the facts. Brain 132: 6-7 [Full Text]  
• Hansen, J. M., Thomsen, L. L., Olesen, J., Ashina, M. (2008). Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 71: 841-847 [Abstract] [Full Text]  
• Schoonman, G. G., van der Grond, J., Kortmann, C., van der Geest, R. J., Terwindt, G. M., Ferrari, M. D. (2008). Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. Brain 131: 2192-2200 [Abstract] [Full Text]  
• Simonetti, M., Giniatullin, R., Fabbretti, E. (2008). Mechanisms Mediating the Enhanced Gene Transcription of P2X3 Receptor by Calcitonin Gene-related Peptide in Trigeminal Sensory Neurons. J. Biol. Chem. 283: 18743-18752 [Abstract] [Full Text]  
• Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., Flores, C. M. (2008). TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons. J. Neurosci. 28: 6231-6238 [Abstract] [Full Text]  
• Goadsby, P. J. (2008). Calcitonin gene-related peptide (CGRP) antagonists and migraine: Is this a new era?. Neurology 70: 1300-1301 [Full Text]  
• Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., Rapoport, A. M., On behalf of the MK-0974 Protocol 004 study group, (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70: 1304-1312 [Abstract] [Full Text]  
• Starr, A., Graepel, R., Keeble, J., Schmidhuber, S., Clark, N., Grant, A., Shah, A. M., Brain, S. D. (2008). A reactive oxygen species-mediated component in neurogenic vasodilatation. Cardiovasc Res 78: 139-147 [Abstract] [Full Text]  
• Bucelli, R. C., Gonsiorek, E. A., Kim, W.-Y., Bruun, D., Rabin, R. A., Higgins, D., Lein, P. J. (2008). Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons. J. Pharmacol. Exp. Ther. 324: 1172-1180 [Abstract] [Full Text]  
• Park, K.-Y., Russo, A. F. (2008). Control of the Calcitonin Gene-related Peptide Enhancer by Upstream Stimulatory Factor in Trigeminal Ganglion Neurons. J. Biol. Chem. 283: 5441-5451 [Abstract] [Full Text]  
• Salvatore, C. A., Hershey, J. C., Corcoran, H. A., Fay, J. F., Johnston, V. K., Moore, E. L., Mosser, S. D., Burgey, C. S., Paone, D. V., Shaw, A. W., Graham, S. L., Vacca, J. P., Williams, T. M., Koblan, K. S., Kane, S. A. (2008). Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. J. Pharmacol. Exp. Ther. 324: 416-421 [Abstract] [Full Text]  
• D'Arco, M., Giniatullin, R., Simonetti, M., Fabbro, A., Nair, A., Nistri, A., Fabbretti, E. (2007). Neutralization of Nerve Growth Factor Induces Plasticity of ATP-Sensitive P2X3 Receptors of Nociceptive Trigeminal Ganglion Neurons. J. Neurosci. 27: 8190-8201 [Abstract] [Full Text]  
• Clifton, M. S., Hoy, J. J., Chang, J., Idumalla, P. S., Fakhruddin, H., Grady, E. F., Dada, S., Corvera, C. U., Bhargava, A. (2007). Role of calcitonin receptor-like receptor in colonic motility and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G36-G44 [Abstract] [Full Text]  
• Bigal, M. E., Lipton, R. B., Holland, P. R., Goadsby, P. J. (2007). Obesity, migraine, and chronic migraine: Possible mechanisms of interaction. Neurology 68: 1851-1861 [Abstract] [Full Text]  
• Moskowitz, M. A. (2007). The 2006 Thomas Willis Lecture: The Adventures of a Translational Researcher in Stroke and Migraine. Stroke 38: 1645-1651 [Full Text]  
• Cottrell, G. S., Padilla, B., Pikios, S., Roosterman, D., Steinhoff, M., Grady, E. F., Bunnett, N. W. (2007). Post-endocytic Sorting of Calcitonin Receptor-like Receptor and Receptor Activity-modifying Protein 1. J. Biol. Chem. 282: 12260-12271 [Abstract] [Full Text]  
• Zhang, Z., Winborn, C. S., Marquez de Prado, B., Russo, A. F. (2007). Sensitization of Calcitonin Gene-Related Peptide Receptors by Receptor Activity-Modifying Protein-1 in the Trigeminal Ganglion. J. Neurosci. 27: 2693-2703 [Abstract] [Full Text]  
• Olesen, J., Baker, M. G, Freund, T., di Luca, M., Mendlewicz, J., Ragan, I., Westphal, M. (2006). Consensus document on European brain research. J. Neurol. Neurosurg. Psychiatry 77: i1-i49 [Abstract] [Full Text]  
• Fabbretti, E., D'Arco, M., Fabbro, A., Simonetti, M., Nistri, A., Giniatullin, R. (2006). Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide.. J. Neurosci. 26: 6163-6171 [Abstract] [Full Text]  
• Strassman, A. M., Levy, D. (2006). Response Properties of Dural Nociceptors in Relation to Headache. J. Neurophysiol. 95: 1298-1306 [Abstract] [Full Text]  
• Goadsby, P. J (2006). Recent advances in the diagnosis and management of migraine. BMJ 332: 25-29 [Full Text]  
• Holland, P. R., Akerman, S., Goadsby, P. J. (2005). Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther. 315: 1380-1385 [Abstract] [Full Text]  
• Goadsby, P. J. (2005). Advances in the understanding of headache. Br Med Bull 73-74: 83-92 [Abstract] [Full Text]  
• Peroutka, S. J. (2005). NEUROGENIC INFLAMMATION AND MIGRAINE: IMPLICATIONS FOR THE THERAPEUTICS. Mol. Interv. 5: 304-311 [Abstract] [Full Text]  
• Mogil, J. S., Miermeister, F., Seifert, F., Strasburg, K., Zimmermann, K., Reinold, H., Austin, J.-S., Bernardini, N., Chesler, E. J., Hofmann, H. A., Hordo, C., Messlinger, K., Nemmani, K. V. S., Rankin, A. L., Ritchie, J., Siegling, A., Smith, S. B., Sotocinal, S., Vater, A., Lehto, S. G., Klussmann, S., Quirion, R., Michaelis, M., Devor, M., Reeh, P. W. (2005). Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc. Natl. Acad. Sci. USA 102: 12938-12943 [Abstract] [Full Text]  
• Pietrobon, D. (2005). Migraine: New Molecular Mechanisms. Neuroscientist 11: 373-386 [Abstract]  
• Akerman, S., Goadsby, P. J. (2005). The Role of Dopamine in a Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther. 314: 162-169 [Abstract] [Full Text]  
• Fischer, M. J. M., Koulchitsky, S., Messlinger, K. (2005). The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigeminal Nucleus. J. Neurosci. 25: 5877-5883 [Abstract] [Full Text]  
• Waeber, C., Moskowitz, M. A. (2005). Migraine as an inflammatory disorder. Neurology 64: S9-S15 [Full Text]  
• Viney, T. J., Schmidt, T. W., Gierasch, W., Sattar, A. W., Yaggie, R. E., Kuburas, A., Quinn, J. P., Coulson, J. M., Russo, A. F. (2004). Regulation of the Cell-specific Calcitonin/Calcitonin Gene-related Peptide Enhancer by USF and the Foxa2 Forkhead Protein. J. Biol. Chem. 279: 49948-49955 [Abstract] [Full Text]